Peptide education
DSIP
Delta sleep-inducing peptide · Emideltide
DSIP stands for delta sleep-inducing peptide, a nine-amino-acid molecule (WAGGDASGE) named in the 1970s for a sleep effect seen in early Swiss animal work. The name stuck; the effect never settled into accepted science. The human record is two small intravenous insomnia studies from 1987 and 1992 with weak results, plus a 2006 review that describes the biology as a riddle. What keeps it selling is the name itself: it sounds like a mechanism, and the marketing treats it as one.
The name is the strongest evidence DSIP has. The human record is two small old IV insomnia studies whose own authors called the effects weak, and nothing modern has arrived to rescue it.
Overview
Quick answer
Historical DSIP sleep studies, modern emideltide compounding discussions, online sleep-recovery marketing, and injectable research products are different contexts. The older insomnia studies used intravenous DSIP under research conditions, while the current FDA materials discuss emideltide/DSIP as a nominated bulk-substance topic with missing safety and product-quality information.
What is DSIP?
A nonapeptide, WAGGDASGE, named for delta-wave sleep effects in early animal research. It also appears as emideltide in current FDA compounding materials. Decades later, its biology is still not characterized as a clean sleep pathway.
Why do people talk about it?
Mostly because of the name. A peptide called delta sleep-inducing sells itself for insomnia, deep sleep, and recovery, and the FDA nomination list added narcolepsy and opioid withdrawal to the conversation. The actual human evidence is two small old insomnia studies.
What routes and amounts appear in the human studies?
Intravenous 25 nmol/kg, in both of them. The 1992 trial dosed in the afternoon before three laboratory nights; the 1987 study dosed across four nights. Nothing about modern subcutaneous, nasal, oral, or bedtime use comes from these papers.
Does DSIP have strong evidence for recovery?
No. Recovery is modern marketing draped over sleep interest. The human studies measured insomnia outcomes, not training or injury recovery, and the review literature describes unresolved biology rather than a recovery pathway.
How do modern claims fit?
Poorly. The studies were IV, short, and old; the products sold now are subcutaneous or nasal, with community doses around 100 to 200 mcg before bed. Different route, different amount basis, different goal: modern practice inherits nothing from the studies except the name.
Reported practice
Commonly reported protocol
Community sleep-protocol ranges. Community-reported patterns, not verified by controlled human trials and not a use recommendation. Full use-pattern detail
Evidence
Evidence snapshot
Two older human insomnia studies are available: a 1992 double-blind study in 16 chronic insomnia patients and a 1987 short-term administration study. Both belong to historical sleep research, not modern consumer guidance.
The 1992 study reported higher sleep efficiency and shorter sleep latency on objective measures, but the authors judged the statistically significant effects weak, with no matching improvement across subjective sleep quality and most other measures.
A later PubMed-indexed review described DSIP as a riddle and emphasized that the sleep-factor hypothesis never became a well-characterized gene, protein, receptor, or pathway model.
The older sequence paper identifies DSIP as a nine-amino-acid peptide with the sequence WAGGDASGE, which helps separate molecule identity from broad sleep, recovery, and withdrawal claims.
The ClinicalTrials.gov search did not identify current DSIP or emideltide trial records, leaving the human evidence dependent on older published sleep studies.
FDA materials flag potential safety and missing-information concerns for nominated peptide bulk substances. For DSIP, that makes identity, route, sterility, concentration, stability, and finished-product controls central issues.
Claims
Common claims vs evidence
| Claim | Human evidence | Mechanistic evidence | Anecdotal evidence | Verdict |
|---|---|---|---|---|
| DSIP is a reliable deep-sleep peptide. | Older human insomnia studies exist, but the 1992 double-blind study was not a decisive clinical win. It found limited objective sleep changes and concluded that short-term DSIP was unlikely to provide major therapeutic benefit for chronic insomnia. | The name and sequence history support a sleep-research origin, but the 2006 review describes DSIP biology as complicated rather than a clear receptor-driven sleep pathway. | Modern online discussion often treats the name as evidence that DSIP deepens sleep. The sleep papers are more modest than the marketing suggests. | DSIP is an older insomnia-research peptide with small, mixed human sleep findings, not a dependable deep-sleep tool. |
| DSIP improves sleep latency and sleep efficiency. | The 1992 double-blind study reported shorter sleep latency and higher sleep efficiency versus placebo on objective measures, but the effects were weak and did not carry across subjective sleep quality or most other measures. | A sleep-associated peptide could plausibly affect sleep architecture, but the mechanism remains poorly characterized. | Sleep-efficiency and sleep-latency language is easy to lift into protocol blogs or product pages, yet the published result was a small older study with limited effects. | Discussable as narrow historical evidence for sleep latency and efficiency, but not a basis for treating DSIP as a broad insomnia treatment. |
| DSIP supports recovery. | The reviewed human studies do not test training recovery, injury recovery, or post-exertional recovery as primary outcomes. | Recovery claims usually borrow from sleep, stress, or neuroendocrine ideas, but the DSIP mechanism support is a review that stresses complicated biology. | Recovery appears in clinic, forum, Reddit, and vendor discussion, but those sources do not provide reliable recovery outcomes or schedules. | Recovery remains an extrapolation from sleep and stress-interest themes because the available sources do not directly test recovery outcomes. |
| DSIP or emideltide helps opioid withdrawal or narcolepsy. | FDA PCAC materials mention proposed emideltide/DSIP uses including opioid withdrawal, chronic insomnia, and narcolepsy, but the reviewed DSIP material does not provide a modern controlled efficacy basis for withdrawal or narcolepsy care. | The references here do not identify a receptor, gene, or confirmed pathway behind a dependable withdrawal or narcolepsy effect. | Withdrawal and narcolepsy claims are high-stakes because they can intersect with standard medical care, dependence, sedation, sleep attacks, and unsafe product substitution. | These are high-caution claims. The FDA materials identify proposed uses and safety gaps; they do not show a withdrawal or narcolepsy regimen. |
| The 25 nmol/kg study amount can be copied into modern DSIP use. | The 25 nmol/kg figure comes from older IV research schedules in chronic insomnia, including three treatment nights in the 1992 laboratory study and four nights in the 1987 short-term study. | Moving that number to another route depends on formulation, peptide stability, body weight, product identity, and exposure. The mechanism literature does not solve those questions. | Modern DSIP discussions often involve non-study products and different routes, so a study amount can be misread as a universal bedtime pattern. | The 25 nmol/kg figure applies only to the historical IV studies; it is not a general bedtime, nasal, oral, or injection regimen. |
| A DSIP vial labeled with a sequence is equivalent to study DSIP. | The human sleep studies used research DSIP in controlled settings; they do not verify every later vial, spray, capsule, or compounded product carrying the DSIP or emideltide name. | Sequence identity alone is insufficient. Concentration, impurities, sterility, endotoxin, stability, route, and container controls all affect risk. | Online product language can compress all of those questions into a single DSIP label or purity claim. | Misleading. Product quality has to be judged separately from molecule name and from old study abstracts. |
Bottom line
Main takeaway
DSIP is a peptide with a great name and a weak record. Two small old studies found limited sleep effects, and the biology behind it was never worked out.
The 25 nmol/kg figure belongs to IV laboratory studies from 1987 and 1992. It does not convert into a subcutaneous bedtime dose, and no modern trial exists to supply one.
The base is thin: the 16-patient 1992 double-blind, the 1987 crossover, the 2006 review that calls DSIP a riddle, the 1978 sequence paper, an empty trial registry, and FDA bulk-substance materials. Start there and expect ambiguity.
Identity
What it is
DSIP is delta sleep-inducing peptide, a nonapeptide with the sequence WAGGDASGE, first isolated in 1970s Swiss sleep research and named for delta-wave effects in animals. In current FDA compounding materials the same molecule appears under the name emideltide.
The human testing happened early and stopped early: a 1987 short-term study and a 1992 double-blind trial, both intravenous 25 nmol/kg in chronic insomnia patients. The 1992 trial did find some objective improvements, shorter sleep latency, better sleep efficiency, and its authors still rated the effects weak, with no matching improvement in subjective sleep quality. A 2006 review concluded the sleep-factor hypothesis never matured into a characterized gene, receptor, or pathway.
Modern DSIP is a market phenomenon built on that thin record. The FDA nomination list connects emideltide to insomnia, narcolepsy, and opioid withdrawal; sellers add recovery; users inject 100 to 200 mcg before bed. None of that comes from the studies.
How people talk about it online
Online, DSIP is a sleep and recovery peptide: bedtime subcutaneous doses, 2 to 4 week runs, sometimes nasal spray, often stacked into broader recovery protocols. The discussions lean on the name as if it were a mechanism.
Read the primary sources and the story shrinks: modest objective changes in a 16-person trial, subjective sleep unchanged, biology unresolved. The gap between the name and the record is the most instructive thing about DSIP.
Use context
Routes, doses, and cycle patterns
The DSIP sources give two useful historical study patterns and several practical unknowns. The human insomnia studies used IV 25 nmol/kg under research conditions. They do not define a modern public-use range for subcutaneous, intranasal, oral, sublingual, or bedtime use.
Human studies and product labels
1992 double-blind chronic-insomnia study
- Purpose
- Chronic insomnia sleep measures
- Context
- Double-blind matched-pairs parallel-group laboratory study
- Route
- Intravenous
- Amount
- 25 nmol/kg body weight
- Frequency
- Once in the afternoon before treatment nights 3, 4, and 5
- Duration
- Five laboratory nights total, with three DSIP or placebo treatment nights
The study reported higher objective sleep efficiency and shorter sleep latency with DSIP, but most measures did not improve and the authors described the statistically significant effects as weak.
1987 short-term chronic-insomnia study
- Purpose
- Short-term sleep improvement in chronic insomnia
- Context
- Older double-blind crossover sleep study
- Route
- Intravenous
- Amount
- 25 nmol/kg or placebo
- Frequency
- During four nights
- Duration
- Four-night administration period
This paper helps show that the historical human DSIP sleep literature used IV exposure and short administration windows, not modern retail peptide schedules.
2006 DSIP review
- Purpose
- Biology and sleep-factor interpretation
- Context
- PubMed-indexed review
- Route
- Not a regimen study
- Amount
- Not a dosing study
- Frequency
- Not a dosing study
- Duration
- Not a dosing study
The review is important because it pulls the sleep claim back from a simple mechanism explanation. DSIP remained a complicated neuroendocrine topic rather than a well-characterized sleep-signaling pathway.
ClinicalTrials.gov DSIP/emideltide search
- Purpose
- Current trial-registry check
- Context
- ClinicalTrials.gov search
- Route
- No matching current trial regimen found
- Amount
- No trial amount found in the registry search
- Frequency
- No trial frequency found in the registry search
- Duration
- No trial duration found in the registry search
The human evidence therefore depends on older published insomnia papers for details rather than a modern registered DSIP development program.
Real-world discussion
Community sleep-protocol ranges
- Purpose
- Sleep and recovery discussion
- Context
- Forums, clinics, and vendor listings
- Route
- Subcutaneous injection, with intranasal use also discussed
- Amount
- Most often around 100 to 200 mcg taken before bed
- Frequency
- Once daily before bed in most descriptions
- Duration
- Often described in 2 to 4 week runs
DSIP has a long but inconclusive research history, and the sleep claims attached to it in marketing exceed the human evidence. The pre-bed timing is built into the compound's premise rather than established by trials. Reported as context, not a recommendation.
What varies
- Route: the human studies used IV DSIP, while many modern products are discussed differently.
- Amount: 25 nmol/kg is a historical study amount, not a universal product amount.
- Duration: the insomnia schedules were measured in nights, not open-ended cycles.
- Goal: insomnia, recovery, narcolepsy, and withdrawal claims require different evidence.
- Product: sequence, purity, sterility, concentration, stability, and route-specific controls all matter.
Human data
Human evidence
Two small old studies are the entire human record: a 1987 crossover and a 1992 double-blind trial in 16 chronic insomnia patients, both IV 25 nmol/kg over a handful of nights. The 1992 study reported better objective sleep efficiency and shorter latency, but the authors rated the significant effects weak, saw no matching subjective improvement, and concluded short-term DSIP was unlikely to give major therapeutic benefit. Nothing has been registered since: the trial-registry search for DSIP and emideltide came back empty. FDA materials list proposed uses and safety gaps, not evidence.
Evidence maturity
DSIP has one of the longest tracks on this site, and the least to show for it.
Named for a sleep effect in early Swiss animal research.
1980s-90s double-blind sleep studies with mixed results.
No modern controlled trials; mechanism still debated.
PCAC voted July 24, 2026 against recommending emideltide for the 503A Bulks List (6-7, one abstention); non-binding.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| 1992 chronic-insomnia double-blind study | 16 chronic insomnia patients | Double-blind matched-pairs parallel-group laboratory study | Research DSIP under controlled study conditions | Objective sleep efficiency improved and sleep latency shortened versus placebo, but subjective sleep quality and most other measures did not change. The authors judged the effects weak. | Small older study, short exposure, IV route, limited outcome consistency, and no modern product-quality bridge to retail or compounded DSIP. | Weak |
| 1987 short-term chronic-insomnia study | Chronic insomnia patients | Older double-blind crossover sleep study | Research DSIP under controlled study conditions | The study is a short-term sleep paper using IV DSIP at 25 nmol/kg or placebo over four nights. | Older study design, limited public detail in the available abstract, IV exposure, and no direct bridge to modern non-study products. | Weak |
| 2006 DSIP biology review | Sleep and DSIP literature | Review | Literature review, not a product study | The review describes DSIP as biologically complicated rather than a simple sleep switch. | Review evidence helps interpret plausibility and uncertainty, but it does not provide a clinical regimen or a modern safety package. | Weak |
| ClinicalTrials.gov DSIP/emideltide search | Current registry search context | Registry search | Current trial-registry check | No current DSIP or emideltide trial records appeared in the registry search. | A registry search cannot rule out research elsewhere; it only explains why the current evidence does not include a registered trial regimen. | Weak |
Cautions
Safety and unknowns
- Modern DSIP products may not match the DSIP used in historical studies in identity, concentration, sterility, stability, impurities, or route.
- The human studies were short and older, so they do not define long-term sleep, endocrine, neuropsychiatric, cardiovascular, withdrawal, or narcolepsy safety.
- The 2006 review keeps core biology complicated, which makes broad mechanism claims weaker than the name implies.
- Withdrawal and narcolepsy claims can affect high-risk medical decisions and do not have a modern DSIP treatment trial in the cited sources.
- A product label, purity claim, or sequence listing still leaves sterile injectable quality, finished-drug controls, and correct concentration to be documented.
Product quality
A vial label is only a starting point
DSIP identity starts with the sequence WAGGDASGE, but finished-product risk depends on much more than sequence.
FDA bulk-substance materials make product-quality and missing-safety questions especially important for peptide substances discussed in compounding contexts.
A modern vial, spray, capsule, or compounded product can differ from the historical IV study material in formulation, route, storage, stability, and exposure.
Identity
Confirms whether the product actually matches DSIP/emideltide rather than a mislabeled or degraded peptide.
Concentration
Sleep studies report nmol/kg IV exposure; modern products may use different units, strengths, and delivery assumptions.
Sterility and endotoxin
Any injectable product has risks that are not resolved by a peptide sequence or headline purity percentage.
Stability
Peptides can degrade with handling, storage, reconstitution, and time.
Route-specific formulation
IV research exposure does not automatically translate to subcutaneous, intranasal, oral, or sublingual products.
Mechanism
How it is proposed to work
DSIP was named because early work connected it with delta-wave sleep activity, but later review literature keeps the mechanism complicated. A clearer summary is that DSIP is a sleep-associated peptide from older research, not a well-defined sleep switch.
The sequence paper identifies DSIP as the nonapeptide WAGGDASGE.
The 2006 review emphasizes that the DSIP sleep hypothesis was never fully characterized through a clearly isolated gene, protein, receptor, or related pathway.
Sleep, recovery, withdrawal, and narcolepsy claims require outcome evidence; they do not follow just from the name or sequence.
DSIP is a nonapeptide first isolated in 1970s Swiss sleep research. Proposed actions include modulation of NMDA and GABA-ergic signaling and stress-axis effects, though its status as a confirmed endogenous sleep factor has been debated for decades.
FAQ
Common questions
Does DSIP help you sleep?
The name promises more than the evidence delivers. Small human studies from the 1980s and 90s reported short-term sleep-related effects, but the literature is old, small, and inconsistent — there is no dependable human evidence for the marketing claims.
What do reported schedules look like?
Community protocols commonly describe 100 to 200 mcg before bed, by subcutaneous injection or intranasally, in 2 to 4 week runs. The pre-bed timing is built into the compound's premise rather than established by trials.
Is DSIP on the FDA compounding agenda?
It was on the July 2026 PCAC agenda as emideltide/DSIP, and on July 24, 2026 the committee voted 6 to 7 against recommending it for the 503A Bulks List (one abstention). The vote is a non-binding advisory recommendation, not an FDA decision: compounding status is unchanged while formal rulemaking proceeds.
Details
Technical details
Sources
References
- 1.
FDA. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee 2026.
Accessed 2026-07-24.
FDA meeting page for the July 23-24, 2026 PCAC review of BPC-157, KPV, TB-500, MOTs-C, emideltide/DSIP, Semax, and Epitalon bulk substances, including the uses evaluated for each, briefing documents, and docket FDA-2025-N-6895.
- 2.
FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks 2026.
Accessed 2026-06-08.
FDA summarizes potential significant safety risks and missing safety information for several nominated peptide bulk substances.
- 3.
PubMed. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study 1992.
PMID:1299794 Accessed 2026-06-08.
Older human insomnia study; keep study context separate from protocol advice.
- 4.
PubMed. Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs 1987.
PMID:3583493 Accessed 2026-06-08.
Older human sleep source; not a public dosing/protocol basis.
- 5.
PubMed. Delta sleep-inducing peptide (DSIP): a still unresolved riddle 2006.
PMID:16539679 Accessed 2026-06-08.
Review emphasizing unresolved DSIP biology.
- 6.
PubMed. The delta EEG (sleep)-inducing peptide (DSIP). XI. Amino-acid analysis, sequence, synthesis and activity of the nonapeptide 1978.
PMID:568769 Accessed 2026-06-08.
Identity/sequence source for DSIP.
- 7.
ClinicalTrials.gov. ClinicalTrials.gov search for DSIP or emideltide 2026.
Accessed 2026-06-08.
No matching DSIP/emideltide clinical trial records were used from the current registry search.